drugset / Trial / NCT06025851
Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
RandomizedSequentialDouble-blindTreatment
Summary
The study is designed to investigate the safety and tolerability of CM-101 for the treatment of medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Timeline
- Start
- 2017-07-24
- Primary completion
- 2018-02-18
- Completion
- 2018-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM-101 | Monoclonal antibody | 0.75 mg/kg | Intravenous |
| Subject | CM-101 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | CM-101 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | CM-101 | Monoclonal antibody | 10 mg/kg | Intravenous |
Indications
No indication recorded.